Reprogrammed Transsulfuration Promotes Basal Like Breast Tumor Progression via Realigning Cellular Cysteine-persulfidation
Dr. Peter Nagy, from the National Institute of Oncology, Hungary, will present his most recent findings on "Reprogrammed Transsulfuration Promotes Basal Like Breast Tumor Progression via Realigning Cellular Cysteine-persulfidation".
Basal Like subtype of Breast Cancers (BLBC) generally lack hormone receptors and HER2. Hence they are resistant towards currently available targeted therapies and represent the most aggressive subtype of breast cancers with poor prognosis.
Protein expression profile analyses in a large cohort of breast cancer patients with a novel quantitative mass spectrometry based method revealed altered expression profile for enzymes of the transsulfuration machinery in BLBCs compared to other subtypes.
Genetic silencing of the highly upregulated CBS enzyme in BLBC cell lines together with comprehensive metabolome analyses revealed that it protects tumor cells hand in hand with CSE against oxidative stress conditions including a novel oxidative cell death called ferroptosis.
CBS also mediates onco-signaling pathways via its Reactive Sulfur Species products with functional aspects in cell proliferation, migration, epithelial-mesenchymal transformation and hypoxic response.
Xenograft studies indicated that these processes translate into tumor progression and aggressiveness and play fundamental roles in angiogenesis, adaptation to hypoxic conditions and tumor cell necrosis.
Therefore, Dr. Nagy's findings could provide new avenues for drug development endeavors in BLBC.
24th Annual ISANH Meeting
Paris Redox 2022 Congress
June 22-24, 2022 - Paris, France
www.isanh.net
